Dark Forest Capital Management LP Buys New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Dark Forest Capital Management LP acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,148 shares of the biopharmaceutical company's stock, valued at approximately $359,000.

A number of other large investors have also recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Amicus Therapeutics during the 3rd quarter worth $107,000. Diversified Trust Co lifted its holdings in shares of Amicus Therapeutics by 9.7% in the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company's stock worth $770,000 after acquiring an additional 7,257 shares during the last quarter. Park Avenue Securities LLC acquired a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $123,000. Avanza Fonder AB bought a new stake in shares of Amicus Therapeutics during the 4th quarter valued at approximately $157,000. Finally, KBC Group NV increased its position in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company cut their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $16.75.

Amicus Therapeutics Trading Down 13.0 %

NASDAQ:FOLD traded down $1.00 on Thursday, reaching $6.68. 10,696,645 shares of the stock traded hands, compared to its average volume of 2,677,144. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -37.11, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 1-year low of $6.20 and a 1-year high of $12.65. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company's 50 day moving average is $8.05 and its 200-day moving average is $9.35.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.